An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
{{output}}
This study reports the first-in-human application of iPSC-derived CD19/BCMA dual-targeting chimeric antigen receptor-natural killer (CAR-NK) cells (QN-139b) in a patient with severe, diffuse cutaneous systemic sclerosis. The allogeneic product was genetically ... ...
